WO2018007945A1 - Solid composition containing oral anticoagulant - Google Patents
Solid composition containing oral anticoagulant Download PDFInfo
- Publication number
- WO2018007945A1 WO2018007945A1 PCT/IB2017/054031 IB2017054031W WO2018007945A1 WO 2018007945 A1 WO2018007945 A1 WO 2018007945A1 IB 2017054031 W IB2017054031 W IB 2017054031W WO 2018007945 A1 WO2018007945 A1 WO 2018007945A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- starch
- rivaroxaban
- sodium
- cellulose
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to the field of Oral pharmaceuticals.
- the invention specifically relates to solid oral anticoagulant compositions and methods for the preparation of the same.
- the present invention more specifically relates to composition of Rivaroxaban Oral tablets and methods for the preparation of the same.
- This invention also relates to the composition of Rivaroxaban Oral tablets prepared by drug layered spheres.
- This invention also relates to the composition of Rivaroxaban tablets prepared by Non-aqueous granulation using Organic solvent and Hydroalcoholic granulation.
- the active ingredient in the present invention is Rivaroxaban chemically known as "5-Chloro-N-( ⁇ (5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-l, 3- oxazolidin-5-yl ⁇ methyl)-2-thiophenecarboxamide" and has an empirical chemical formula C 19 H 18 ClN 3 O 5 S with a structural formula shown below:
- Rivaroxaban is a low molecular weight, orally administrable anticoagulant indicated for reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation and prophylaxis of deep vein thrombosis. It is an orally bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation.
- US 2008/0026057 disclose a solid, orally administrable pharmaceutical composition, comprising rivaroxaban in hydrophilized form.
- This application further discloses a process for the preparation of composition comprising Rivaroxaban in hydrophilized form, in which (a) first granules comprising the Rivaroxaban in hydrophilized form are prepared by moist granulation (b) and the granules are then converted into the pharmaceutical composition, if appropriate with addition of pharmaceutically suitable additives.
- US 2010/0151011 disclose rapid release solid pharmaceutical dosage form of rivaroxaban containing drug in amorphous form or thermodynamic ally metastable crystal modification form. Use of these modified forms increases the solubility and the oral bioavailability of rivaroxaban.
- US 2011/0300214 disclose pharmaceutical compositions of rivaroxaban comprising a solubilizer and a pseudo-emulsifier.
- US 2012/0231076 disclose process for producing a pharmaceutical composition of rivaroxaban. The process involves mixing rivaroxaban, a matrix former, and a disintegrant, melting the mixture, and granulating the melted mixture.
- US 2013/0064888 disclose pharmaceutical dosage forms of rivaroxaban having a compressed inert core, an optional subcoat over the compressed inert core, a drug layer over the compressed core.
- WO 2010/146179 disclose solid pharmaceutical compositions of rivaroxaban, prepared by dry mixing or dry granulation of the rivaroxaban with at least one excipient, co-milling rivaroxaban with the excipients, hot melt granulation with a molten excipient, or hot melt extrusion with an excipient. The mixture may then be agglomerated, granulated with a granulation liquid, or milled before compressing to form a tablet.
- WO 2015/124995 Al disclose an oral solid dosage form of rivaroxaban, prepared by a process, comprising the steps of blending, granulation, drying, milling and formulating the blend obtained into solid dosage form.
- the main objective of the present invention is to provide an oral solid dosage form of rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients.
- Another objective of the present invention is to provide a process for the Preparation of solid dosage form of rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts.
- Another objective of the invention is to provide an alternative pharmaceutical composition of rivaroxaban and its method of preparation which will enhance the dissolution and oral bioavailability of the drug.
- One embodiment of the present invention provides an oral pharmaceutical composition comprising Rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts prepared by drug layering technology.
- an oral pharmaceutical composition comprising Rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts prepared by non-aqueous granulation and hydroalcoholic granulation.
- an oral pharmaceutical composition comprising Rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts prepared by non-aqueous granulation/ Hydroalcoholic granulation containing cremophore.
- an oral pharmaceutical composition comprising Rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, diluents/fillers, binders, disintegrants, glidants, lubricants, surfactants, solubilizers and other excipients.
- an oral pharmaceutical composition comprising rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, prepared by a process comprising steps of: a) Dissolving excipients in mixture of ethanol and Purified water,
- step 1 Dispersing drug in step 1 solution until smooth dispersion forms
- step 3 Adding extragranular materials to step 3 pellets and blend followed by compression and optional coating.
- an oral pharmaceutical composition comprising rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, prepared by a process comprising steps of: a) Dissolving Hydroxypropyl cellulose, Croscarmellose sodium and Sodium lauryl sulphate in mixture of ethanol and Purified water,
- step 2 Dispersing Rivaroxaban in step 1 solution until smooth dispersion forms, c) Spraying step 2 dispersion on to sugar pellets in Fluid bed dryer,
- step 4 blend d) Adding extragranular materials to step 3 pellets and blend, e) Compressing the tablets using step 4 blend,
- step 5 Coating the tablets of step 5 with step 6 dispersion.
- an oral pharmaceutical composition comprising rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, prepared by a process comprising steps of: a) Preparing binder solution,
- step 2 dispersion on to step 3 blend until proper granules obtains
- an oral pharmaceutical composition comprising rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, prepared by a process comprising steps of: a) Dissolving Hydroxypropyl cellulose and Cremophor in ethanol or mixture of Ethanol and Purified water,
- step 1 Dispersing Rivaroxaban in step 1 solution until smooth dispersion forms, c) Sifting Croscarmellose sodium, Lactose monohydrate and microcrystalline cellulose,
- step 2 dispersion on to step 3 blend in Fluid bed dryer until proper granules obtained
- step 4 Adding extragranular materials to step 4 granules and blend, and
- the invention specifically relates to oral anticoagulant compositions and methods for the preparation of the same.
- One embodiment of the present invention provides an oral pharmaceutical composition comprising Rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, diluents, binders, disintegrants, glidants, lubricants, surfactants, solubilizers and other excipients.
- process for the preparation of oral solid composition comprising rivaroxaban its solvates, hydrates and/or pharmaceutically acceptable salts, diluents, binders, disintegrants, glidants, lubricants, surfactants and other excipients.
- rivaroxaban includes various forms of rivaroxaban such as hydrates, solvates, polymorphs, isomers, stereoisomers, enantiomers, racemates, esters, prodrugs, complexes or mixture thereof and all other forms known in the art.
- Rivaroxaban can be present in different physical forms, e.g. in an amorphous form, in one or several crystal form (s) (e.g. anhydrous, solvated or hydrated forms), in the form of mixture of different crystal forms (e.g. anhydrous, solvated or hydrated forms) or as a mixture of an amorphous form and crystal form (s) (e.g. anhydrous, solvated or hydrated forms).
- crystal form e.g. anhydrous, solvated or hydrated forms
- crystal form e.g. anhydrous, solvated or hydrated forms
- crystal form e.g. anhydrous, solvated or hydrated forms
- crystal form e.g.
- composition according to the invention comprise diluents such as microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), compressible sugar, fructose, dextranes, other sugars such as mannitol, sorbitol, lactitol, saccharose or a mixture thereof, siliconised microcrystalline cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate or mixtures thereof.
- diluents such as microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), compressible sugar, fructose, dextranes, other sugars such as mannitol, sorbitol, lactitol, saccharose or a mixture thereof, siliconised microcrystalline cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate or mixtures thereof.
- a preferred further diluent that also causes reduced sticking properties of tablets to the equipment used for tabletting is silica, preferably colloidal or fumed silica.
- composition according to the invention comprise binders, such as polyvinyl pyrollidone, polyvinylpyrrolidone/vinyl acetate copolymer, polyvinyl alcohol, polymers of acrylic acid and its salts, starch, celluloses and celluloses derivatives like methylcellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyl propyl cellulose, ethylhydroxyethylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose etc., maltrin, sucrose solution, dextrose solution, acacia, tragacanth, locust bean gum, gelatine, guar gum, starch, pregelatinised starch, partially hydrolysed starch, alginates, xanthan or polymethacrylate, or mixtures thereof. It is preferable to use a binder with good water solubility.
- the excipients include at least one binder selected from hydroxypropyl cellulose and
- composition according to the invention comprise disintegrants, such as carboxymethylcellulose, carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked sodium carboxymethyl cellulose as e.g. Ac-Di-Sol®, Primellose®, Pharmacelt® XL, Explocel®, and Nymcel® ZSX having a molecular weight of 90 000-700 000, sodium starch glycolate e.g.
- disintegrants such as carboxymethylcellulose, carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked sodium carboxymethyl cellulose as e.g. Ac-Di-Sol®, Primellose®, Pharmacelt® XL, Explocel®, and Nymcel® ZSX having a molecular weight of 90 000-700 000, sodium starch glycolate e.g.
- Explosol®, Explotab®, Glycolys®, Primojel®, Tablo®, Vivastar® P in particular having molecular weight is 500000-11000000, crosslinked polyvinylpolypyrrolidone (Plasone-XL®, Polyplasdone® XL and Kollidon® CL) in particular having a molecular weight in excess of 1000000, more particularly having a particle size distribution of less than 400 microns or less than 74 microns, microcrystalline cellulose, L-HPC (low -substituted hydroxypropylcellulose), sodium carboxymethyl starch, sodium glycolate of potato starch, partially hydrolysed starch, wheat starch, maize starch, rice starch or potato starch, cornstarch, pregelatinized starch, crospovidone, for example, POLYPLASDONE XL® (International Specialty Products), magnesium aluminium silicate or mixtures thereof.
- Plasone-XL® Polyplasdone® XL and
- composition according to the invention also comprise lubricants, such as stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulphate, hydrogenated vegetable oil, hydrogenated castor oil, sodium stearyl fumarate, macrogols, or mixtures thereof.
- lubricants such as stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulphate, hydrogenated vegetable oil, hydrogenated castor oil, sodium stearyl fumarate, macrogols, or mixtures thereof.
- glidants such as talc, fumed silica, magnesium stearate, stearic acid, kaolin, magnesium trisilicate either alone or in combination thereof.
- composition according to the invention also comprise surfactants, such as sodium salts of fatty alcohol sulphates such as sodium lauryl sulphate; or sulphosuccinates such as sodium dioctyl sulpho succinate; or partial fatty acid esters of polyhydric alcohols such as glycerol mono stearate, glyceryl monooleate, glyceryl monobutyrate; or block copolymers of ethylene oxide and propylene oxide, also known as polyoxyethylene polyoxypropylene block copolymers or polyoxyethylene polypropyleneglycol, such as Poloxamer 124, Poloxamer 188, Poloxamer 237, Poloxamer 388, Poloxamer 407 (BASF Wyandotte Corp.); or fatty acid esters of sorbitan such as sorbitan mono laurate, sorbitan monopalmitate, sorbitan monooleate, sorbitan stearate, sorbitan monolaurate etc.
- polyoxyethylene (20) sorbitan such as Span or Arlacel , Emsorb®, Capmul®, or Sorbester®, Triton X-200 etc.; or a fatty acid esters of polyhydroxyethylene sorbitan such as polyoxyethylene (20) sorbitan, e.g. polyoxyethylene (20) sorbitan monooleate (Tween® 80), polyoxyethylene (20) sorbitan monostearate (Tween®60), polyoxyethylene (20) sorbitan monopalmitate (Tween® 40), polyoxyethylene (20) sorbitan monolaurate (Tween® 20); or polyethylene glycol fatty acid esters, e.g.
- polyoxyethyleneglycerol triricinoleate or polyoxyl 35 castor oil (Cremophor® EL; BASF Corp.); or polyoxyethyleneglycerol oxystearate such as polyethylenglycol 40 hydrogenated castor oil (Cremophor RH® 40) or polyethylenglycol 60 hydrogenated castor oil (Cremophor RH® 60); or sucrose fatty acid esters, such as sucrose stearate, sucrose oleate, sucrose palmitate, sucrose laurate, and sucrose acetate butyrate; or vitamin E and its derivatives such as Vitamin E-TPGS® (d- alpha- tocopheryl polyethylene glycol 1000 succinate); or phospholipids, glycerophospholipids (lecithins, kephalins, phosphatidyl serine), glyceroglycolipids (galactopyransoide), sphingophospholipids (sphingomyelin), and s
- acylcarnitines and derivatives N-a-acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N-a-acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N-a-acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof.
- Each one of these specific surface- active agent constitutes an alternative embodiment of the invention.
- composition according to the invention also comprise solubilizers such as sugar alcohols like isomalt, sorbitol, xylitol or mannitol, cellulose derivatives (especially hydroxypropylmethyl cellulose (HPMC) and/or hydroxypropyl cellulose (HPC)), sugar alcohols (especially isomalt), polyethoxylated castor oil (Cremophor), polyvinylpyrrolidone and copolymers of polyvinylpyrrolidone are used as solubilizer.
- solubilizers such as sugar alcohols like isomalt, sorbitol, xylitol or mannitol, cellulose derivatives (especially hydroxypropylmethyl cellulose (HPMC) and/or hydroxypropyl cellulose (HPC)), sugar alcohols (especially isomalt), polyethoxylated castor oil (Cremophor), polyvinylpyrrolidone and copolymers of polyvinylpyrrolidone are
- composition according to the invention also comprise solvents such as methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and the like and mixtures thereof.
- the pharmaceutical composition of the present invention can be present in the form of a tablet, a capsule, powder, a disc, a caplet, granules, pellets, granules in a capsule, minitablets, minitablets in a capsule, pellets in a capsule, a sachet and other dosage forms suitable for oral administration.
- the granules may be prepared by methods such as, but not limited to, wet granulation, melt granulation, dry granulation or roll compaction or the like.
- cores/tablets can be coated with conventional materials used for film coating, i. e. as described in "Pharmaceutical Coating Technology", 1995, edited by Graham Cole.
- Film coating formulations usually contain the following components: polymer (s), plasticizer (s), colourant (s) /opacifier (s), vehicle (s). In film coating suspension the minor quantities of flavours, surfactants and waxes can be used.
- the majority of the polymers used in film coating are either cellulose derivatives, such as the cellulose ethers, or acrylic polymers and copolymers.
- Typical cellulose ethers are hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and methylcellulose.
- Acrylic polymers comprise a group of synthetic polymers with diverse functionalities. Some of them can be further modified to enhance swelling and permeability by the incorporation of materials such as water soluble cellulose ethers and starches in order to ensure complete disintegration/ dissolution of the film.
- additives used in the preparations to the compositions of this invention can be used and there were no limitations: stabilizer, surfactant, plasticizer, lubricant, reducing agent, buffer agent, sweetening agent, base, adsorbent, corrigent, binder, suspending agent, antioxidant, polish, coating, wetting agent, wet modifier, filler, antifoaming agent, refrigerative agent, coloring matter, flavoring agent, perfume, sugar coating agent, isotonizing agent, softener, emulsifying agent, foaming agent, pH modifier, anti-frothing agents, diluent, excipient, dispersing agent, disintegrator, fragrance, desiccant, antiseptics, preservative, solubilizing agent, solubilizer
- Example 1 S.No Ingredients Quantity in mg per tablet
- Spraying step 2 dispersion on to sugar pellets in Fluid bed dryer
- step 3 4. Adding extragranular materials to step 3 pellets and blend,
- step 4 Compressing the tablets using step 4 blend, Dispersing Opadry brown in Purified water, and
- step 2 dispersion on to step 3 blend in Fluid bed dryer until proper granules obtains
- step 5 Add extragranular materials to step 4 granules and blend, 6. Compress the tablets using step 5 blend,
- step 6 Coat the tablets of step 6 with step 7 dispersion.
- step 2 Disperse Rivaroxaban in step 1 solution until smooth dispersion forms, 3. Sift together Croscarmellose sodium, Lactose monohydrate and microcrystalline cellulose,
- step 2 dispersion on to step 3 blend in Fluid bed dryer until proper granules obtains, 5. Add extragranular materials to step 4 granules and blend,
- step 6 Coat the tablets of step 6 with step 7 dispersion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3028346A CA3028346A1 (en) | 2016-07-05 | 2017-07-04 | Solid composition containing oral anticoagulant |
BR112019000187A BR112019000187A2 (en) | 2016-07-05 | 2017-07-04 | solid composition containing oral anticoagulant |
ZA2019/00719A ZA201900719B (en) | 2016-07-05 | 2019-02-04 | Solid composition containing oral anticoagulant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641023129 | 2016-07-05 | ||
IN201641023129 | 2016-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018007945A1 true WO2018007945A1 (en) | 2018-01-11 |
Family
ID=60912395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/054031 WO2018007945A1 (en) | 2016-07-05 | 2017-07-04 | Solid composition containing oral anticoagulant |
Country Status (4)
Country | Link |
---|---|
BR (1) | BR112019000187A2 (en) |
CA (1) | CA3028346A1 (en) |
WO (1) | WO2018007945A1 (en) |
ZA (1) | ZA201900719B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1009619B (en) * | 2018-05-09 | 2019-10-23 | Φαρμαζακ Α.Φ.Ε.Β.Ε. | Pharmaceutical composition containing rivaroxaban and method for the preparation thereof |
WO2022259118A1 (en) * | 2021-06-10 | 2022-12-15 | Shilpa Medicare Limited | Fast dissolving oral film preparation comprising rivaroxaban |
WO2023067620A1 (en) * | 2021-10-18 | 2023-04-27 | Unison Pharmaceuticals Pvt. Ltd. | Orally disintegrating pharmaceutical compositions of rivaroxaban |
CN116327726A (en) * | 2023-02-24 | 2023-06-27 | 沈阳药科大学 | Platelet membrane coated bionic nano-particle and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026065A1 (en) * | 2004-12-24 | 2007-02-01 | Bayer Healthcare Ag | Solid, modified-release pharmaceutical dosage forms which can be administered orally |
US20080026057A1 (en) * | 2003-11-27 | 2008-01-31 | Bayer Healthcare Ag | Process for the Preparation of a Solid, Orally Administrable Pharmaceutical Composition |
WO2010146179A2 (en) * | 2009-06-18 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
US20110189279A1 (en) * | 2008-08-11 | 2011-08-04 | Ratiopharm Gmbh | Pharmaceutical compositions with modified release properties comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
US20130281457A1 (en) * | 2008-07-08 | 2013-10-24 | Ratiopharm Gmbh | Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
-
2017
- 2017-07-04 BR BR112019000187A patent/BR112019000187A2/en not_active IP Right Cessation
- 2017-07-04 WO PCT/IB2017/054031 patent/WO2018007945A1/en active Application Filing
- 2017-07-04 CA CA3028346A patent/CA3028346A1/en not_active Abandoned
-
2019
- 2019-02-04 ZA ZA2019/00719A patent/ZA201900719B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080026057A1 (en) * | 2003-11-27 | 2008-01-31 | Bayer Healthcare Ag | Process for the Preparation of a Solid, Orally Administrable Pharmaceutical Composition |
US20070026065A1 (en) * | 2004-12-24 | 2007-02-01 | Bayer Healthcare Ag | Solid, modified-release pharmaceutical dosage forms which can be administered orally |
US20130281457A1 (en) * | 2008-07-08 | 2013-10-24 | Ratiopharm Gmbh | Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
US20110189279A1 (en) * | 2008-08-11 | 2011-08-04 | Ratiopharm Gmbh | Pharmaceutical compositions with modified release properties comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
WO2010146179A2 (en) * | 2009-06-18 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1009619B (en) * | 2018-05-09 | 2019-10-23 | Φαρμαζακ Α.Φ.Ε.Β.Ε. | Pharmaceutical composition containing rivaroxaban and method for the preparation thereof |
WO2022259118A1 (en) * | 2021-06-10 | 2022-12-15 | Shilpa Medicare Limited | Fast dissolving oral film preparation comprising rivaroxaban |
WO2023067620A1 (en) * | 2021-10-18 | 2023-04-27 | Unison Pharmaceuticals Pvt. Ltd. | Orally disintegrating pharmaceutical compositions of rivaroxaban |
CN116327726A (en) * | 2023-02-24 | 2023-06-27 | 沈阳药科大学 | Platelet membrane coated bionic nano-particle and preparation method and application thereof |
CN116327726B (en) * | 2023-02-24 | 2024-02-02 | 沈阳药科大学 | Platelet membrane coated bionic nano-particle and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
ZA201900719B (en) | 2022-02-23 |
BR112019000187A2 (en) | 2019-04-24 |
CA3028346A1 (en) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6061438B2 (en) | Pharmaceutical composition containing diamine derivative | |
EP2442799B1 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
WO2018007945A1 (en) | Solid composition containing oral anticoagulant | |
EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
EP2033629B1 (en) | Solid pharmaceutical composition comprising valsartan | |
US9937153B2 (en) | Oral pharmaceutical formulation of omarigliptin | |
US9918975B2 (en) | Method for improving dissolution of anticoagulant agent | |
US8449896B2 (en) | Pharmaceutical composition having improved solubility | |
JP2011098964A5 (en) | ||
US20100136119A1 (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
TWI592154B (en) | Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions | |
EP2808011A1 (en) | Process for the preparation of a pharmaceutical composition comprising Rivaroxaban | |
EP2266541A1 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
KR102206104B1 (en) | Granule comprising silodosin, and pharmaceutical composition and formulation comprising the same | |
KR20160026714A (en) | Choline alfoscerate-containing tablet and process for preparing the same | |
EP3292863A1 (en) | Solid pharmaceutical dosage form comprising sofosbuvir | |
JPH1192369A (en) | Pharmaceutical preparation, its production and use of acidic additive for stabilization of cilansetron | |
AU2002214524B2 (en) | Capsule of cellulose derivatives such as HPMC containing benzimidazole derivatives such as omeprazole | |
EP2568970B1 (en) | Stable pharmaceutical formulations containing an antihistaminic | |
WO2014115082A1 (en) | Pharmaceutical formulations of imatinib | |
AU2002214524A1 (en) | Capsule of cellulose derivatives such as HPMC containing benzimidazole derivatives such as omeprazole | |
WO2014053974A1 (en) | Pharmaceutical compositions of sirolimus | |
JP2020045323A (en) | Solifenacin succinate-containing preparation | |
JP6272328B2 (en) | Candesartan cilexetil-containing preparation | |
US20070299054A1 (en) | Oral pharmaceutical composition of a poorly water-soluble active agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17823736 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3028346 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019000187 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112019000187 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190104 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17823736 Country of ref document: EP Kind code of ref document: A1 |